Dog Point Man from Elon Musk is now MDMA Consigliere

Antonio Grassyas, Elon Musk’s close ally and Tesla (Tesla) Member of the Board of Directors, and it has been focused on a Controversial acquisition From Lykos Therapeutics, a biotechnology company that develops MDMA treatments once by the FDA for safety concerns, The Guardian Reports.

Since the drug industry towards prevailing acceptance reveals new developments on how to form policy, science and industrial interests for the future of mental health treatments.

But Gracias is involved in the company’s organizational body now is to lift the eyebrows, Guardian reports.

Likos, who announced a $ 50 million redemption earlier this year, was at the forefront of some promising research with the help of MDMA. But the recent rejection of the company in its clinical experiences, which were martyred Disadvantages associated with bias and experimental designShe complained about her prospects for approval.

Thank you very much for discussions on scientific rigor, the agency ordered New Phase 3 testIt is possible that it takes several years and costs millions.

The company’s opponents argue that the flawed science has led to rejection, while supporters believe in the therapeutic capabilities of MDMA under the appropriate organization.

Lykos nor Gracias did not respond to a comment.

The “wheel lubrication” of the organization?

The last Gracias leadership of Lykos, funded by a $ 50 million leak, is supported by wealthy investors, including hedge funds and veteran executives, arrive as Republican officials and Democrats both to the approval temperature faster on narcotic drugs.

Some senior health officials in the Trump era, such as former officials and legislators, I supported publicly Re -evaluation of the organizational process, referring to promising early results and sick demand.

This is to raise warning bells with ethics experts.

“You cannot split the wheels and then say,” Well, I will now resign and follow this approval, “said Cennatia Brown, the senior ethics lawyer in the group of monitoring of non -profit actors. Tell the trustee.

This political support fuel fears about politicizing science. Critics warn that relaxation is FDA criteria or rapid tracking approvals under the influence of those who are aware of the industry can undermine the safety of scientific research, and the risk of relapses in the future if safety is at risk.

“The challenge is to ensure that the enthusiasm is not out of evidence,” as Mason Marx, a law professor at Harvard University specializes in drug policy, Tell the trustee. “Science must remain independent of politics to avoid making the entire industry in a bad condition.”

At the same time, Grassyas’s relations with musk and the army, along with his previous work in the government, raised questions about conflicting interests amid pressure for organizational reform.

Will the Food and Drug Administration be reviewed now?

The FDA now has a wide discretionary power to reconsider its previous decisions, or to issue urgent emergency statements or reviews, creating opportunities for companies such as Lykos to accelerate their way to the market.

“The maps and Gracias will try to seize the moment we enter”, IFETAYO HARVEY, a former maps employee and executive director of the COLOR SMORTORELIC Collective people, He said. “I think the goal is to obtain psychotherapy with the help of MDMA by the Food and Drug Administration by any necessary means.”

Gracias shares some few questions for the prosperous drug industry.

It stands at the crossroads: whether progress will be under politicization, but promising or proceeding with caution to ensure safety and effectiveness in the long run. Since political numbers make fun of deepening public interest in mental health and wellness, those who are familiar with the industry and the organizers face an accurate balance between hope, harm, progress and wisdom.

“With the lack of transparency, it really leaves us in what it means to be Doug,” said Fieth Williams, the project’s policy manager on government oversight, a non -profit monitoring group. Tell the trustee.. ))

The magic of the man’s burning

Rick Dulain, founder and president of the multidisciplinary association for narcotic studies (maps) and a long -term defender for research and therapeutic use of narcotic drugs. Dulain said he immediately saw a partnership.

“It was the magic of the burning man,” Doblin He said. “I was looking for a white knight that would come and focus more on healing and public benefit.”

In that spring, Lykos Therapeutics announced a great leadership leadership, appointed the new CEO and chief medical official and restructuring its board of directors. These moves arrived as Gracias and investor Christopher Hohn took control.

“Gracias is actively involved in the company’s daily operations,” a map director whose name has not been revealed and the beginning of the industry, Tell the trustee. They said this focuses on the influence of Gracias now on the strategic direction of the company because it aims to restore organizational confidence and accelerate clinical experiences.

This leadership shift confirms the high bets and the intense industry interest in drug science, where supporters and critics are closely monitoring while the company is moving in complex organizational and scientific obstacles.

But more than unusual, the company’s supporters were accused of an effort to collect donations that are allegedly involved in drug use with investors.

“Certainly part of their fundraising strategy is” the wealthy meeting in Burning Man, and the anesthetic with them and obtaining maps money “,” Harvey, Executive Assistant to Doblin in 2015, Tell the trustee.

Maps treat drug allegations with investors

Maps have denied that they use medications as a way to scorch investment.

“The maps are conducting all the activities of collecting donations with the highest integrity and maintaining strict moral boundaries in all donor relationships and donation collection activities. Maps do not provide control materials in any events or gatherings, and we do not use materials as a tool or strategy to collect donations,” maps said in a statement.

Doblin also Tell Business Insider last year Giving drugs to the donors was “not common.”